Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: This disclosure is directed to the topical/transdermal administration of the phytochemical, Withaferin A (WFA), for its wide range of pharmacological applications to include its anti-cancer, anti-obesity, anti-diabetic, anabolic effect on osteoporotic bone and its many other proteasomal inhibitory effects.

Abstract: Improved formulations that combine chemical permeation enhancers with additional agents so that the formulations simultaneously penetrate both lipid and cellular matrices provide effective transdermal delivery of active agents.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: A light applicator configured for contacting a portion of a subject's body surface and applying light irradiation thereto for lipolysis of target tissue underlying the subject's body surface is provided. The light applicator includes: a substrate; a plurality of light emitting diodes (LEDs) arranged on the substrate. A beam divergence of each of the plurality of LEDs is in the range of 50 to 70 steridian. The plurality of LEDs is arranged such that their emitted light beams overlap during transmission to a target tissue underlying the subject's body surface.

Abstract: A light applicator configured for contacting a portion of a subject's body surface and applying light irradiation thereto for lipolysis of target tissue underlying the subject's body surface is provided. The light applicator includes: a substrate; a plurality of light emitting diodes (LEDs) arranged on the substrate. A beam divergence of each of the plurality of LEDs is in the range of 50 to 70 steradian. The plurality of LEDs is arranged such that their emitted light beams overlap during transmission to a target tissue underlying the subject's body surface.

Abstract: Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents, including compositions promoting collagen biosynthesis, retinoids and skin lighteners, chemical denervation agents such as BOTOX®, anti-fungal agents, anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, these topical compositions may be used in combination with non-ablative treatment modalities, such as microdermabrasion, laser-based skin remodeling and radio-frequency-based skin remodeling.

Abstract: Methods and apparatus are provided that prevent or inhibit functional regression caused by the stromal remodeling resulting from epithelial or fibroblastic apoptosis or necrosis in patients who will undergo or have undergone a thermal ciliary muscle tendinoplasty or scleral collagen shrinkage procedures. Methods and compositions are provided that prevent apoptosis in epithelial cells by stromal cooling during thermal tendinoplasty procedures; that create or restore stabilizing molecular cross-links between scleral stromal lamellar fibers; and that interrupt at least one step in the stromal remodeling response including inhibition of apoptosis, fibroblastic proliferation and migration, and inhibition of collagenesis.

Abstract: Methods and apparatus are provided that prevent or inhibit functional regression caused by the stromal remodeling resulting from epithelial or fibroblastic apoptosis or necrosis in patients who will undergo or have undergone a thermal ciliary muscle tendinoplasty or scleral collagen shrinkage procedures. Methods and compositions are provided that prevent apoptosis in epithelial cells by stromal cooling during thermal tendinoplasty procedures; that create or restore stabilizing molecular cross-links between scleral stromal lamellar fibers; and that interrupt at least one step in the stromal remodeling response including inhibition of apoptosis, fibroblastic proliferation and migration, and inhibition of collagenesis.

Abstract: A system and method for the treatment of ocular collagen connective tissue comprises identifying a portion of the ocular collagen connective tissue having a connector portion which transitions into the ciliary muscle and the lens of an eye. A source of energy is then directed at at least one selected site along the portion of the connective tissue, the amount of energy being sufficient to cause longitudinal shrinkage in the length of connective tissue.

Abstract: A caffeine detector comprises a reaction medium and a reagent impregnated in at least a portion of the reaction medium. The reagent provides the reaction medium with a color which is changed when a liquid containing a threshold amount of caffeine reacts with the reagent.

Abstract: A system and method for the treatment of ocular collagen connective tissue comprises identifying a portion of the ocular collagen connective tissue having a connector portion which transitions into the ciliary muscle and the lens of an eye. A source of energy is then directed at at least one selected site along the portion of the connective tissue, the amount of energy being sufficient to cause longitudinal shrinkage in the length of connective tissue.

Abstract: A cooling handpiece and method for use in therapeutic, cosmetic or aesthetic, diagnostic, exploratory, interventional or other medical procedures, the handpiece for use in conjunction with a controllable energy source such as coherent light, non-coherent light or laser light, ultrasound energy, radio frequency energy and other types of electromagnetic and mechanical energy, the handpiece comprising a main body portion adapted for directing the energy to target tissue, the main body portion further adapted for receiving a removable reservoir containing coolant fluid, the reservoir having an attachment means for releasable attachment of the reservoir to the handpiece, and the handpiece having a controllable valve for delivery of a portion of the coolant fluid to the target tissue.